DYSF and Duchenne muscular dystrophy: Since statin inhibition of muscle wasting in dystrophin-deficient mdx models of DMD remains controversial [15, 16], we tested simvastatin in the Dysf-null model of LGMD2B between 2 and 11 months, under both normolipidemic chow and hyperlipidemic HFD conditions.